Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.


TSXV:RX - Post by User

Bullboard Posts
Post by bthoughtson Sep 30, 2014 11:58am
159 Views
Post# 22982699

Thanks

Thanks

Hey everyone,

Thanks lscfa, microcap, theinvestor22 and the rest of the gang for your reply and insights.

Questions:

1) lscfa - in your previous post you said "Yes, out-licensing products to international markets is exciting. RX market size is no longer restricted to small Canadian marketplace"

I just wanted to confirm to make sure I understood RX business model. What I understand so far is RX license existing products from outside of Canada, and then sells them to the Canadian market.

When you said out-licensing products to international markets, does this mean RX is planning to license Canadian products outside to international markets? If so when did they state this was happening?

2) If you had $10,000 to invest. Would you invest in RX, CXR, GUD, TWD or something else? So far those seem to be my current picks but I can't decide. RX and TWD are on the venture exchange and I'm very iffy about the voltility and nature of the exchange. CXR has done great, but that doesnt mean it will continue to do good, as I used thinking before for MCR and so far got screwed. GUD seems like they have potential from their team and background, but so far hasn't really done anything and are sitting on cash.

What would you recommend to do, split the $10,000 into each of them, focus on one, invest in none and just wait. 

As an overall look at markets, a lot of things seem to be fairly or over valued and it's been 7 years of bullmarket, just fearing an impending major correction or crash. If you can share insights and opinon that would be great.

Thanks again for your time and help.

 

Bullboard Posts